Morning research
https://t.me/stockradarGapping down
In reaction to disappointing earnings/guidance:
- DSW -18.3%,SIG -16.5%,TWMC -13.5%,CPB -6.9%,ZTO -6.5%,CHS -6.5%,BECN -4%, A-3.9%, TEDU-2.4%, BURL-2.4%, PDCO-2.4%, DAKT-1.9%, LOW-1.8%, CRH-1.3%, URBN-1%, INTU-0.8%
Other news:
- CYTK -29.7% (announces that VITALITY-ALS Phase 3 clinical trial of tirasemtiv in patients with amyotrophic lateral sclerosis did not meet the primary endpoint)
- PFGC -2.2% (prices 5 mln common stock offering by selling stockholder Wellspring Capital at $28.25/share)
- DGX -2.2% (Quest Diagnostics details impact of Medicare payment rates for clinical laboratory tests; expects impact to be approx 4% in 2018 and 10% 2019-2020; to host call tomorrow)
Analyst comments:
- TER -1.5% (downgraded to Hold at Deutsche Bank)
Gapping up
In reaction to strong earnings/guidance:
- CMCM+15.1%, ASYS+13.7%, PTNR+11.6%, EVLV+8.6%, PANW+7.6%, FANH+4.1%, JEC+4.1%, BLRX+3.8%, HRL+2.9%, GOGL+1.7%, VIPS+1.3%, DSX+1.3%, CO+1.2%
M&A news:
- STLY +8.1% (Stanley Furniture to sell substantially all of its assets to Churchill Downs)
Other news:
- OHGI +19% (One Horizon confirms it is now in full compliance with the applicable NASDAQ Listing Requirements)
- AVXL +6.3% (reports new data published on Alzheimer's Disease demonstrate the neuroprotective features of the Sigma-1 receptor)
- CPRX +3.3% (announces phase 2 study of Firdapse)
- ATOM +2.1% (reported customer pipeline growth)
- KMDA +1.6% (signs a supply agreement with an undisclosed international organization for KamRAB will extend through 2020)
- VALE +0.9% (announces extension of the negotiation period with Federal Prosecutors)
Analyst comments:
- CLSN +38.8% (initiated with Outperform at Oppenheimer)
- KTOV +21.3% (upgraded to Buy at H.C. Wainwright; tgt $10 (stock closed at 1.97 on Monday))
- SNSS +9.8% (initiated with Outperform at Oppenheimer)
- VRTV +2.8% (upgraded to Buy at BofA/Merrill)
- GTXI +2.1% (initiated with Outperform at Robert W. Baird)